Developer docs
API playgroundTry for free, no card

Search company profiles

LSK Global PS

Full company profile

uuid0024s71

Namestring
LSK Global PS
Legal namestring
LSK Global Pharma Services Co., Ltd.
Websiteurl
lskglobal.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

LSK Global PS (legal name: LSK Global Pharma Services Co., Ltd.) is a Korea-headquartered, full-service Contract Research Organization providing end-to-end clinical development services for pharmaceutical and biotech sponsors. The company originated in 2000 as Westat Korea, became Lifecord Stat-Korea, Inc. in 2001, and adopted its current name in 2006. It serves as a one-stop CRO covering the entire drug development lifecycle across 14 service modules: consulting, medical services, medical writing, regulatory affairs, project management, study start-up, clinical operations, data management, biostatistics, post-marketing surveillance/observational studies, pharmacovigilance, quality assurance, academic research services, and training. Its customer base spans domestic Korean pharma, international pharma with Korea programs, and Korean biotech pursuing global development, with named enterprise relationships including GC Corp, INT Therapeutics, and Daewoong Pharmaceutical.

The technology stack is anchored on best-in-class third-party platforms — Medidata Rave, Target e*Studio, Oracle InForm, Oracle Argus, Veeva Vault, Medidata CTMS, Medidata Intelemage, ArisGlobal Safety Database, and the MediLake CDISC platform — supplemented by LSK's proprietary LSK V1Z data visualization tool. The company is a Medidata channel partner and a CDISC member, with FDA 21 CFR Part 11 compliant systems and direct US FDA SDTM submission experience. Wholly-owned subsidiaries (LSK NRDO, LSK SMO) and overseas branches (LSK Taiwan for data management; LSK PV EU in Warsaw, Poland for European pharmacovigilance) support its global delivery model, alongside the Asia CRO Alliance and partner CRO networks across North America, EU, Japan, China, and Southeast Asia.

The business model is project-based, professional-services revenue earned through direct enterprise contracts negotiated by the Business Development department. Pricing is quote-based and customized by indication, phase, site count, and subject count, with multi-year contract cadences typical of full-service CRO engagements. The company holds a stack of "first-in-Korea" regulatory certifications (ISO 9001, 37001, 37301, 27001, 14155, CCDM Industry Partner, KoNECT Innovative CRO) plus the only EMA direct-reporting pharmacovigilance qualification among Korean CROs, all of which are actively renewed (most recently ISO 27001 in January 2026 and family-friendly certification in 2026). The company is privately held with no disclosed external investors or parent company, founded and led by Young Jack Lee, a former NIH Biostatistics Branch Chief.

Short descriptiontext

LSK Global PS is a privately held Korean full-service Contract Research Organization providing end-to-end clinical trial, regulatory, data management, biostatistics, and pharmacovigilance services to domestic and international pharmaceutical and biotech sponsors, with overseas branches in Taiwan and Poland.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, clinical trial management, pharmacovigilance services, regulatory affairs consulting
Industry1 code
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Clinical Trial Services
TypeProfessional Services
Description

Full-service CRO providing Phase I-III registration trials, investigator-initiated studies, Phase IV and post-marketing surveillance, observational studies, and consulting services for new drug development. Revenue generated through project-based contracts with pharmaceutical and biotech sponsors.

lskglobal.com
2Regulatory Affairs Services
TypeProfessional Services
Description

IND/NDA package preparation, submission, regulatory authority review management, and approval support. Includes US FDA, EMA, and Korean MFDS regulatory strategy consulting.

lskglobal.com
3Pharmacovigilance Services
TypeProfessional Services
Description

Safety monitoring, ICSR processing, PSUR/PBRER development, PV audit, and Eudravigilance reporting services. Includes EMA direct reporting capabilities.

lskglobal.com
4Education and Training Services
TypeProfessional Services
Description

Clinical trial monitor training programs approved by MFDS, including CRA training, QA training, and customized training for pharmaceutical companies and institutions.

lskglobal.com
5Academic Research Services
TypeProfessional Services
Description

Research design, data management, statistical analysis, manuscript writing, and statistical consulting for pharmaceutical and medical academic research.

lskglobal.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based custom pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Estimation requests handled by Business Development department. Typically requires indication, phase, number of sites, and number of subjects for quote preparation.

lskglobal.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LSK Global PS is a full-service Contract Research Organization (CRO) providing end-to-end clinical drug development services for pharmaceutical and biotech sponsors. The company delivers an integrated platform covering the entire clinical trial lifecycle—from drug development consulting, regulatory affairs, medical writing, and study start-up through Phase I–IV clinical operations, data management, biostatistics, pharmacovigilance, quality assurance, and post-marketing surveillance. Services are sold via custom project-based contracts negotiated through the Business Development department.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Surpassed 1,000 clinical trial contracts milestone in 2018
+1 more record
Product overview1 text field

LSK Global PS operates as a comprehensive one-stop full-service CRO (Contract Research Organization) platform providing end-to-end clinical development services from early consulting through post-marketing surveillance. The platform is organized around 14 integrated service modules: Drug Development Consulting, Medical Service, Medical Writing, Regulatory Affairs, Project Management, Study Start-Up, Clinical Operation, Data Management, Biostatistics, Epidemiological Research for PMS/OS, Pharmacovigilance, Quality Assurance, Academic Research Service (ARS), and Training. Key technology-enabled service components include Medidata Rave EDC, Oracle InForm, Oracle Argus safety management, Target e*Studio eCRF, Veeva Vault Clinical Applications, and the proprietary LSK V1Z data visualization tool. LSK Global PS is a Medidata Channel Partner and CDISC member, with an EU pharmacovigilance branch in Warsaw, Poland and a Data Management branch in Taiwan.

Product and service17 records
1Full-Service CRO Platform
CategoryContract Research Organization Services
Description

Comprehensive one-stop full-service CRO platform covering the entire drug development lifecycle from initial consulting and preclinical strategy through Phase I–IV clinical trials, post-marketing surveillance, and observational studies. Integrates consulting, regulatory affairs, clinical operations, data management, biostatistics, pharmacovigilance, and training services for pharmaceutical and biotech sponsors.

2Drug Development Consulting Service
3Medical Service
4Medical Writing Service
CategoryMedical Writing Services
Description

Ethical and scientific protocol development for Phase I–IV clinical studies, medical device trials, health functional food studies, observational studies, and post-marketing surveillance. Also produces clinical study reports including statistical analysis and clinical interpretation.

5Regulatory Affairs Service
CategoryRegulatory Affairs Services
Description

Regulatory affairs support covering domestic and international regulations for clinical trial conduct and product registration, including IND/NDA package preparation, FDA/MFDS regulatory strategy, and EMA regulatory management.

6Project Management Service
CategoryProject Management Services
Description

Comprehensive project management including planning, timeline management, quality management, risk management, and vendor management to coordinate clinical trials from initiation to close-out.

7Study Start-Up Service
CategoryStudy Start-Up Services
Description

Specialized study start-up services including feasibility assessment, IRB initial submission, site budget negotiation, and clinical trial agreement execution, managed by dedicated SSU specialists.

8Clinical Operation Service
CategoryClinical Operations Services
Description

Full site management covering pre-study visits, initiation visits, regular monitoring, and close-out visits, employing risk-based monitoring, centralized monitoring, and on-site monitoring approaches.

9Data Management Service
CategoryData Management Services
Description

Full-service clinical data management from CRF development through CDM system configuration, operation, and management. Includes eCRF design, Medidata Rave and Oracle InForm EDC systems, medical coding (MedDRA/WHODrug), SAE reconciliation, CDISC SDTM/ADaM conversion, and LSK V1Z data visualization. LSK Global PS is a Medidata Channel Partner and CDISC member.

10Biostatistics Service
CategoryBiostatistics Services
Description

Comprehensive biostatistics services including study design, sample size calculation, statistical analysis plan development, CDISC ADaM dataset generation, statistical programming (SAS), TFL production, and analysis report writing. Staffed by 6 PhD statisticians and multiple senior statisticians.

11Epidemiological Research for PMS/OS Service
CategoryEpidemiological Research Services
Description

Specialized post-marketing observational study services including regulatory PMS, reexamination studies, prospective and retrospective observational studies, surveys, and chart reviews, delivered by a dedicated epidemiological research department established in 2010.

12Pharmacovigilance Service
CategoryPharmacovigilance Services
Description

Comprehensive PV services from first-in-human through post-marketing, including SAE processing, ICSR management, PSMF, DSUR, PBRER, RMP, EudraVigilance direct reporting, and PV audit. Includes a dedicated EU branch in Warsaw, Poland, established May 2019, enabling direct EMA safety reporting. LSK Global PS holds the only EMA direct-reporting qualification among Korean CROs.

13Quality Assurance Service
CategoryQuality Assurance Services
Description

ICH-GCP-based independent audits, internal quality management, vendor assessment, SOP development, and consulting services. All QA auditors hold RQAP-GCP certification.

14Academic Research Service (ARS)
CategoryAcademic Research Services
Description

Full-cycle academic research support from study planning and design through data management, statistical analysis, and manuscript publication. Includes EDC-based study management, SAP development, and statistical consulting for academic medical researchers.

15Training Service
CategoryTraining Services
Description

Systematic education programs for clinical research professionals including CRA (monitor) training, QA training, biostatistics workshops, and customized corporate training. LSK Education Center is MFDS-designated as a clinical trial education institution since August 2016.

16LSK V1Z Data Visualization Service
CategoryData Visualization Services
Description

Proprietary tailored clinical data visualization and reporting service that transforms complex clinical trial data into intuitive visual reports using graphs, color-coded indicators, and interactive dashboards to support monitoring, early risk signal detection, and data-driven decision-making.

17Oracle Argus Safety Case Management Solution
CategoryPharmacovigilance Technology Services
Description

Pharmacovigilance safety case management service powered by Oracle Argus, processing over 10 million safety cases annually with AI-powered features designed to enhance efficiency and data privacy.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership24 partners
1원스글로벌 (ONES Global)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-08
Description

MOU for data-based clinical research cooperation. Aims to enhance successful execution and capacity building for clinical trials and new drug development through evidence-based approaches.

lskglobal.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-18
Description

MOU for strengthening clinical trial and regulatory strategy. Collaboration to enhance new medicine development and regulatory expertise.

3서울대학교병원
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

CDISC Seoul Interchange 2024 session presentation on CDISC standard utilization.

lskglobal.com
4서울아산병원 항암유효성평가지원센터 (APEX)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-28
Description

MOU for enhancing new drug commercialization success rate and fulfilling efficacy evaluation demand. Joint symposiums on next-generation oncology conducted annually.

lskglobal.com
5중앙대학교
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

MOU for activation and development of medical statistics and clinical trial field cooperation.

lskglobal.com
6재인알앤피 (Jaein RNL)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-15
Description

Strategic MOU for new drug development and global clinical research cooperation.

lskglobal.com
7아주대병원
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-28
Description

MOU for activation of domestic medical device clinical trials.

lskglobal.com
8고려대학교 구로병원
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-18
Description

MOU for domestic pharmaceutical and medical device clinical trial development.

lskglobal.com
9연세의료원 연구개발자문센터
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-12
Description

MOU for healthcare big data utilization in clinical research.

lskglobal.com
10건국대학교 산학협력단
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-29
Description

MOU for establishing industry-academia cooperation system.

lskglobal.com
11뉴클릭스바이오 (Nuclix Biosciences)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-10-26
Description

MOU for innovative anticancer drug development based on prototype mRNA technology.

lskglobal.com
12대웅제약 (Daewoong Pharmaceutical)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-21
Description

MOU for joint clinical development cooperation of COVID-19 treatment 'Foistar Tab' (Camostat Mesylate).

lskglobal.com
13질병관리청
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-21
Description

Joint development partner with GC녹십자 for world's first recombinant anthrax vaccine '배리트락스주'. Awarded Grand Prize at 27th Korea New Drug Development Awards.

lskglobal.com
14고려대학교 의료원 산학협력단
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-20
Description

MOU for clinical trial industry cultivation and mutual cooperation.

lskglobal.com
15연세대학교 의과대학 강남세브란스병원
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-27
Description

MOU for clinical trial cooperation and research outcomes partnership.

lskglobal.com
16타겟헬스 (Target Health)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2019-06-25
Description

Clinical research and regulatory consulting partnership. Joint seminars conducted annually including LSK Global PS year-end conference.

lskglobal.com
17지엔티파마 (GNT Pharma)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-11-22
Description

Strategic partnership for joint new drug research and development.

lskglobal.com
18켐온 (Chemon)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-11-16
Description

Strategic partnership for non-clinical service CRO cooperation to maximize joint research and development capabilities.

lskglobal.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-08-29
Description

MOU for strategic expansion of pharmaceutical market services.

20Asia CRO Alliance (ACA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2010-01-01
Description

Asia CRO Alliance comprising CROs from Korea, Japan, Taiwan, Vietnam, Malaysia. Provides understanding of local regulatory requirements and clinical trial environments across Asia.

lskglobal.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2010-01-01
Description

Alliance agreement for global clinical development support.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2010-01-01
Description

Channel partner agreement for clinical technology solutions including CTMS, eTMF, and Intelemage imaging services.

23MDS Pharma Services (Canada)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2001-01-01
Description

Partnership for clinical research services.

lskglobal.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2000-01-01
Description

Original parent company partnership. LSK Global PS originated as Westat Korea branch before becoming independent.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global CRO with strong APAC presence and oncology/biotech focus; competes with LSK for Korean pharma globalization programs. Comparable on full-service clinical, regulatory, PV, and biopharma services.

TypeBroad incumbent
Description

Global full-service CRO (post-PRA Health Sciences merger) competing head-to-head with LSK on Phase I-IV multinational trials. Comparable on data management (Medidata-academic) and oncology/biotech client segments.

TypeBroad incumbent
Description

Large global clinical and commercial solutions provider. Comparable functional overlap with LSK across Phase I-IV operations, biostatistics, PV, and consulting for global pharma/biotech sponsors.

TypeDirect peer
Description

Mid-to-large global CRO with strong oncology, regulatory, and biostatistics capabilities — most direct functional overlap with LSK's full-service Phase I-IV offering, including proprietary technology platforms and PhD-led operational model.

TypeRegional player
Description

Japan's largest CRO, also operating as a CDMO with full-service clinical, PV, and consulting capabilities. Closest Asia regional peer to LSK given comparable scale, multi-country coverage, and breadth of service modules.

TypeEmerging player
Description

Mid-sized global CRO with strong oncology/hematology focus and European/Asia footprint; comparable as a specialized full-service player competing for multinational biotech oncology and rare disease trials.

TypeDirect peer
Description

Asia-focused CRO with global delivery network and strategic alliance with LSK since 2010 for global clinical development support. Directly comparable on Asia-centric multi-country trials and clinical operations.

TypeBroad incumbent
Description

Post-Labcorp spin-off global CRO covering clinical development, central labs, and PV — comparable to LSK's Medidata/CDISC data management, central laboratory experience, and global trial capabilities.

TypeBroad incumbent
Description

Largest global CRO/C DMO with end-to-end clinical and real-world evidence services; competes with LSK for multinational sponsors and is expanding in Korea/APAC. Comparability via full-service clinical operations, data management, and PV offerings.

TypeEmerging player
Description

Early-phase clinical research specialist focused on FIH, PK/PD, and integrated clinical pharmacology. Comparable to LSK's early-phase oncology operations and FIH multinational trial experience.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration11 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LSK Global PS

Contract Research Organization (CRO) Serviceslskglobal.com

LSK Global PS is a privately held Korean full-service Contract Research Organization providing end-to-end clinical trial, regulatory, data management, biostatistics, and pharmacovigilance services to domestic and international pharmaceutical and biotech sponsors, with overseas branches in Taiwan and Poland.

What LSK Global PS does

LSK Global PS (legal name: LSK Global Pharma Services Co., Ltd.) is a Korea-headquartered, full-service Contract Research Organization providing end-to-end clinical development services for pharmaceutical and biotech sponsors. The company originated in 2000 as Westat Korea, became Lifecord Stat-Korea, Inc. in 2001, and adopted its current name in 2006. It serves as a one-stop CRO covering the entire drug development lifecycle across 14 service modules: consulting, medical services, medical writing, regulatory affairs, project management, study start-up, clinical operations, data management, biostatistics, post-marketing surveillance/observational studies, pharmacovigilance, quality assurance, academic research services, and training. Its customer base spans domestic Korean pharma, international pharma with Korea programs, and Korean biotech pursuing global development, with named enterprise relationships including GC Corp, INT Therapeutics, and Daewoong Pharmaceutical.

The technology stack is anchored on best-in-class third-party platforms — Medidata Rave, Target e*Studio, Oracle InForm, Oracle Argus, Veeva Vault, Medidata CTMS, Medidata Intelemage, ArisGlobal Safety Database, and the MediLake CDISC platform — supplemented by LSK's proprietary LSK V1Z data visualization tool. The company is a Medidata channel partner and a CDISC member, with FDA 21 CFR Part 11 compliant systems and direct US FDA SDTM submission experience. Wholly-owned subsidiaries (LSK NRDO, LSK SMO) and overseas branches (LSK Taiwan for data management; LSK PV EU in Warsaw, Poland for European pharmacovigilance) support its global delivery model, alongside the Asia CRO Alliance and partner CRO networks across North America, EU, Japan, China, and Southeast Asia.

The business model is project-based, professional-services revenue earned through direct enterprise contracts negotiated by the Business Development department. Pricing is quote-based and customized by indication, phase, site count, and subject count, with multi-year contract cadences typical of full-service CRO engagements. The company holds a stack of "first-in-Korea" regulatory certifications (ISO 9001, 37001, 37301, 27001, 14155, CCDM Industry Partner, KoNECT Innovative CRO) plus the only EMA direct-reporting pharmacovigilance qualification among Korean CROs, all of which are actively renewed (most recently ISO 27001 in January 2026 and family-friendly certification in 2026). The company is privately held with no disclosed external investors or parent company, founded and led by Young Jack Lee, a former NIH Biostatistics Branch Chief.

LSK Global PS firmographics

Firmographics
Name
LSK Global PS
Legal name
LSK Global Pharma Services Co., Ltd.
Website
https://lskglobal.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
LSK Global PS is a privately held Korean full-service Contract Research Organization providing end-to-end clinical trial, regulatory, data management, biostatistics, and pharmacovigilance services to domestic and international pharmaceutical and biotech sponsors, with overseas branches in Taiwan and Poland.
Ownership category
akta.pro rank

LSK Global PS industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Clinical research services
  • Contract research organization
  • Clinical trial management
  • Pharmacovigilance services
  • Regulatory affairs consulting

Where LSK Global PS is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

LSK Global PS business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Services: Full-service CRO providing Phase I-III registration trials, investigator-initiated studies, Phase IV and post-marketing surveillance, observational studies, and consulting services for new drug development. Revenue generated through project-based contracts with pharmaceutical and biotech sponsors.
  2. Regulatory Affairs Services: IND/NDA package preparation, submission, regulatory authority review management, and approval support. Includes US FDA, EMA, and Korean MFDS regulatory strategy consulting.
  3. Pharmacovigilance Services: Safety monitoring, ICSR processing, PSUR/PBRER development, PV audit, and Eudravigilance reporting services. Includes EMA direct reporting capabilities.
  4. Education and Training Services: Clinical trial monitor training programs approved by MFDS, including CRA training, QA training, and customized training for pharmaceutical companies and institutions.
  5. Academic Research Services: Research design, data management, statistical analysis, manuscript writing, and statistical consulting for pharmaceutical and medical academic research.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based custom pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

LSK Global PS product offering

Product offering

Core offering

LSK Global PS is a full-service Contract Research Organization (CRO) providing end-to-end clinical drug development services for pharmaceutical and biotech sponsors. The company delivers an integrated platform covering the entire clinical trial lifecycle—from drug development consulting, regulatory affairs, medical writing, and study start-up through Phase I–IV clinical operations, data management, biostatistics, pharmacovigilance, quality assurance, and post-marketing surveillance. Services are sold via custom project-based contracts negotiated through the Business Development department.

Product overview

LSK Global PS operates as a comprehensive one-stop full-service CRO (Contract Research Organization) platform providing end-to-end clinical development services from early consulting through post-marketing surveillance. The platform is organized around 14 integrated service modules: Drug Development Consulting, Medical Service, Medical Writing, Regulatory Affairs, Project Management, Study Start-Up, Clinical Operation, Data Management, Biostatistics, Epidemiological Research for PMS/OS, Pharmacovigilance, Quality Assurance, Academic Research Service (ARS), and Training. Key technology-enabled service components include Medidata Rave EDC, Oracle InForm, Oracle Argus safety management, Target e*Studio eCRF, Veeva Vault Clinical Applications, and the proprietary LSK V1Z data visualization tool. LSK Global PS is a Medidata Channel Partner and CDISC member, with an EU pharmacovigilance branch in Warsaw, Poland and a Data Management branch in Taiwan.

Differentiator

Problem solved

Functional benefit

Products and services

  • Full-Service CRO Platform Comprehensive one-stop full-service CRO platform covering the entire drug development lifecycle from initial consulting and preclinical strategy through Phase I–IV clinical trials, post-marketing surveillance, and observational studies. Integrates consulting, regulatory affairs, clinical operations, data management, biostatistics, pharmacovigilance, and training services for pharmaceutical and biotech sponsors.
  • Drug Development Consulting Service
  • Medical Service
  • Medical Writing Service Ethical and scientific protocol development for Phase I–IV clinical studies, medical device trials, health functional food studies, observational studies, and post-marketing surveillance. Also produces clinical study reports including statistical analysis and clinical interpretation.
  • Regulatory Affairs Service Regulatory affairs support covering domestic and international regulations for clinical trial conduct and product registration, including IND/NDA package preparation, FDA/MFDS regulatory strategy, and EMA regulatory management.
  • Project Management Service Comprehensive project management including planning, timeline management, quality management, risk management, and vendor management to coordinate clinical trials from initiation to close-out.
  • Study Start-Up Service Specialized study start-up services including feasibility assessment, IRB initial submission, site budget negotiation, and clinical trial agreement execution, managed by dedicated SSU specialists.
  • Clinical Operation Service Full site management covering pre-study visits, initiation visits, regular monitoring, and close-out visits, employing risk-based monitoring, centralized monitoring, and on-site monitoring approaches.
  • Data Management Service Full-service clinical data management from CRF development through CDM system configuration, operation, and management. Includes eCRF design, Medidata Rave and Oracle InForm EDC systems, medical coding (MedDRA/WHODrug), SAE reconciliation, CDISC SDTM/ADaM conversion, and LSK V1Z data visualization. LSK Global PS is a Medidata Channel Partner and CDISC member.
  • Biostatistics Service Comprehensive biostatistics services including study design, sample size calculation, statistical analysis plan development, CDISC ADaM dataset generation, statistical programming (SAS), TFL production, and analysis report writing. Staffed by 6 PhD statisticians and multiple senior statisticians.
  • Epidemiological Research for PMS/OS Service Specialized post-marketing observational study services including regulatory PMS, reexamination studies, prospective and retrospective observational studies, surveys, and chart reviews, delivered by a dedicated epidemiological research department established in 2010.
  • Pharmacovigilance Service Comprehensive PV services from first-in-human through post-marketing, including SAE processing, ICSR management, PSMF, DSUR, PBRER, RMP, EudraVigilance direct reporting, and PV audit. Includes a dedicated EU branch in Warsaw, Poland, established May 2019, enabling direct EMA safety reporting. LSK Global PS holds the only EMA direct-reporting qualification among Korean CROs.
  • Quality Assurance Service ICH-GCP-based independent audits, internal quality management, vendor assessment, SOP development, and consulting services. All QA auditors hold RQAP-GCP certification.
  • Academic Research Service (ARS) Full-cycle academic research support from study planning and design through data management, statistical analysis, and manuscript publication. Includes EDC-based study management, SAP development, and statistical consulting for academic medical researchers.
  • Training Service Systematic education programs for clinical research professionals including CRA (monitor) training, QA training, biostatistics workshops, and customized corporate training. LSK Education Center is MFDS-designated as a clinical trial education institution since August 2016.
  • LSK V1Z Data Visualization Service Proprietary tailored clinical data visualization and reporting service that transforms complex clinical trial data into intuitive visual reports using graphs, color-coded indicators, and interactive dashboards to support monitoring, early risk signal detection, and data-driven decision-making.
  • Oracle Argus Safety Case Management Solution Pharmacovigilance safety case management service powered by Oracle Argus, processing over 10 million safety cases annually with AI-powered features designed to enhance efficiency and data privacy.

Quantifiable outcome

  • Surpassed 1,000 clinical trial contracts milestone in 2018
  • +1 more outcomes

Companies that use LSK Global PS

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

LSK Global PS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability4 records

Feature8 records

LSK Global PS partnerships and signals

Strategic signal

Partnerships

24 partnerships are on record, tiered core and minor.

  • 원스글로벌 (ONES Global)coreStrategic or Co-development Partner · 8 April 2025MOU for data-based clinical research cooperation. Aims to enhance successful execution and capacity building for clinical trials and new drug development through evidence-based approaches.
  • Certara KoreacoreStrategic or Co-development Partner · 18 February 2025MOU for strengthening clinical trial and regulatory strategy. Collaboration to enhance new medicine development and regulatory expertise.
  • 서울대학교병원minorStrategic or Co-development Partner · 12 November 2024CDISC Seoul Interchange 2024 session presentation on CDISC standard utilization.
  • 서울아산병원 항암유효성평가지원센터 (APEX)coreStrategic or Co-development Partner · 28 August 2024MOU for enhancing new drug commercialization success rate and fulfilling efficacy evaluation demand. Joint symposiums on next-generation oncology conducted annually.
  • 중앙대학교minorStrategic or Co-development Partner · 1 July 2024MOU for activation and development of medical statistics and clinical trial field cooperation.
  • 재인알앤피 (Jaein RNL)minorStrategic or Co-development Partner · 15 September 2022Strategic MOU for new drug development and global clinical research cooperation.
  • 아주대병원minorStrategic or Co-development Partner · 28 January 2022MOU for activation of domestic medical device clinical trials.
  • 고려대학교 구로병원minorStrategic or Co-development Partner · 18 January 2022MOU for domestic pharmaceutical and medical device clinical trial development.
  • 연세의료원 연구개발자문센터minorStrategic or Co-development Partner · 12 January 2022MOU for healthcare big data utilization in clinical research.
  • 건국대학교 산학협력단minorStrategic or Co-development Partner · 29 November 2021MOU for establishing industry-academia cooperation system.
  • 뉴클릭스바이오 (Nuclix Biosciences)minorStrategic or Co-development Partner · 26 October 2021MOU for innovative anticancer drug development based on prototype mRNA technology.
  • 대웅제약 (Daewoong Pharmaceutical)coreStrategic or Co-development Partner · 21 January 2021MOU for joint clinical development cooperation of COVID-19 treatment 'Foistar Tab' (Camostat Mesylate).
  • 질병관리청coreStrategic or Co-development Partner · 21 January 2021Joint development partner with GC녹십자 for world's first recombinant anthrax vaccine '배리트락스주'. Awarded Grand Prize at 27th Korea New Drug Development Awards.
  • 고려대학교 의료원 산학협력단minorStrategic or Co-development Partner · 20 January 2021MOU for clinical trial industry cultivation and mutual cooperation.
  • 연세대학교 의과대학 강남세브란스병원coreStrategic or Co-development Partner · 27 March 2020MOU for clinical trial cooperation and research outcomes partnership.
  • 타겟헬스 (Target Health)coreTechnology or Integration · 25 June 2019Clinical research and regulatory consulting partnership. Joint seminars conducted annually including LSK Global PS year-end conference.
  • 지엔티파마 (GNT Pharma)minorStrategic or Co-development Partner · 22 November 2017Strategic partnership for joint new drug research and development.
  • 켐온 (Chemon)minorStrategic or Co-development Partner · 16 November 2017Strategic partnership for non-clinical service CRO cooperation to maximize joint research and development capabilities.
  • DKSH KoreaminorChannel Partner/ Reseller/ Distributor · 29 August 2017MOU for strategic expansion of pharmaceutical market services.
  • Asia CRO Alliance (ACA)coreStrategic or Co-development Partner · 1 January 2010Asia CRO Alliance comprising CROs from Korea, Japan, Taiwan, Vietnam, Malaysia. Provides understanding of local regulatory requirements and clinical trial environments across Asia.
  • MakroCareminorStrategic or Co-development Partner · 1 January 2010Alliance agreement for global clinical development support.
  • Medidata Solutions, InccoreTechnology or Integration · 1 January 2010Channel partner agreement for clinical technology solutions including CTMS, eTMF, and Intelemage imaging services.
  • MDS Pharma Services (Canada)minorStrategic or Co-development Partner · 1 January 2001Partnership for clinical research services.
  • Westat IncminorStrategic or Co-development Partner · 1 January 2000Original parent company partnership. LSK Global PS originated as Westat Korea branch before becoming independent.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

LSK Global PS competitors and assessment

Company assessment

Broad incumbents

  • Parexel International: Major global CRO with strong APAC presence and oncology/biotech focus; competes with LSK for Korean pharma globalization programs. Comparable on full-service clinical, regulatory, PV, and biopharma services.
  • ICON plc: Global full-service CRO (post-PRA Health Sciences merger) competing head-to-head with LSK on Phase I-IV multinational trials. Comparable on data management (Medidata-academic) and oncology/biotech client segments.
  • Syneos Health: Large global clinical and commercial solutions provider. Comparable functional overlap with LSK across Phase I-IV operations, biostatistics, PV, and consulting for global pharma/biotech sponsors.
  • Labcorp Drug Development (Fortrea): Post-Labcorp spin-off global CRO covering clinical development, central labs, and PV — comparable to LSK's Medidata/CDISC data management, central laboratory experience, and global trial capabilities.
  • IQVIA Holdings: Largest global CRO/C DMO with end-to-end clinical and real-world evidence services; competes with LSK for multinational sponsors and is expanding in Korea/APAC. Comparability via full-service clinical operations, data management, and PV offerings.

Direct peers

  • Medpace Holdings: Mid-to-large global CRO with strong oncology, regulatory, and biostatistics capabilities — most direct functional overlap with LSK's full-service Phase I-IV offering, including proprietary technology platforms and PhD-led operational model.
  • MakroCare: Asia-focused CRO with global delivery network and strategic alliance with LSK since 2010 for global clinical development support. Directly comparable on Asia-centric multi-country trials and clinical operations.

Regional players

  • CMIC Holdings: Japan's largest CRO, also operating as a CDMO with full-service clinical, PV, and consulting capabilities. Closest Asia regional peer to LSK given comparable scale, multi-country coverage, and breadth of service modules.

Emerging players

  • PSI CRO: Mid-sized global CRO with strong oncology/hematology focus and European/Asia footprint; comparable as a specialized full-service player competing for multinational biotech oncology and rare disease trials.
  • Celerion: Early-phase clinical research specialist focused on FIH, PK/PD, and integrated clinical pharmacology. Comparable to LSK's early-phase oncology operations and FIH multinational trial experience.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

LSK Global PS social profiles

Digital presence

LSK Global PS compliance and trust

Trust signal

Compliance10 records

LSK Global PS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LSK Global PS leadership team

Management profile

Number of profiles

Profiles10 records

LSK Global PS subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

LSK Global PS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LSK Global PS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LSK Global PS

What does LSK Global PS do?

LSK Global PS is a full-service Contract Research Organization (CRO) providing end-to-end clinical drug development services for pharmaceutical and biotech sponsors. The company delivers an integrated platform covering the entire clinical trial lifecycle—from drug development consulting, regulatory affairs, medical writing, and study start-up through Phase I–IV clinical operations, data management, biostatistics, pharmacovigilance, quality assurance, and post-marketing surveillance. Services are sold via custom project-based contracts negotiated through the Business Development department.

Is LSK Global PS a public or private company?

LSK Global PS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was LSK Global PS founded?

LSK Global PS was founded in 2000. It employs 101 to 250 people.

Where is LSK Global PS based?

LSK Global PS is headquartered in Seoul, South Korea, in the Asia region.

How does LSK Global PS make money?

Five revenue lines are on record. Clinical Trial Services are the primary driver. The others are regulatory Affairs Services, pharmacovigilance Services, education and Training Services and academic Research Services.

Who are LSK Global PS's main competitors?

Broad incumbents on record are Parexel International, ICON plc, Syneos Health, Labcorp Drug Development (Fortrea) and IQVIA Holdings. Direct peers are Medpace Holdings and MakroCare. CMIC Holdings is listed as a regional player. Emerging players are PSI CRO and Celerion.

Does LSK Global PS have an API?

No public API is recorded for LSK Global PS.

What industry is LSK Global PS in?

LSK Global PS's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate[Health&] 신약 개발 동반자 'CRO'…이제 초기부터 함께 설계한다 : 네이트 뉴스CROs are expanding from clinical trial operations to early-stage drug development strategy, as domestic pharma firms invest 10-15% of first-half revenue in R&D. LSK Global PS reorganized its clinical science development team and hired experts, broadening its scope to include early clinical entry and AI/ML. The industry expects CROs' role to grow as domestic firms expand globally.Naver[Health&] 신약 개발 동반자 ‘CRO’...이제 초기부터 함께 설계한다CROs are expanding their role to co-design clinical trials from early development, as domestic pharma companies invest 10-15% of first-half revenue in R&D. LSK Global PS has restructured its clinical science development team and hired experts, while 60% of domestic pharma firms using CROs in 2024 chose Korean CROs.NaverLSK "성공적 임상개발 위한 통합전략 학회발표"LSK's Kim Seon-woo, CSD head, will present at KIC 2026 on Oct 15 on designing successful clinical trials. He will cover integrating scientific strategy with trial execution, including patient needs, design elements, and new methods like AI and DCT. LSK aims to strengthen its role as a strategic partner for domestic pharma and biotech.OracleLSK Global Pharma Services Selects Oracle Argus for Safety Case ManagementLSK Global Pharma Services has chosen Oracle Argus to manage its pharmacovigilance operations, aiming to improve safety database management and regulatory compliance. Oracle Argus processes over 10 million safety cases annually and introduces new AI-powered features designed to enhance efficiency and data privacy.PR NewswireLSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced HepatocellularLSK BioPharma and Jiangsu Hengrui Medicine announced a global clinical collaboration to evaluate the combination of LSKB's rivoceranib and Hengrui's camrelizumab for treating patients with advanced hepatocellular carcinoma. Under the agreement, Hengrui will conduct the clinical trial and share costs with LSKB, which retains global rights for rivoceranib outside of China while Hengrui keeps commercial rights for camrelizumab. This collaboration aims to enhance treatment options for patients suffering from a condition with high unmet medical needs.PR NewswireLSK BioPharma's Apatinib Receives Orphan Drug Designation in the European UnionLSK BioPharma announced that the European Commission granted orphan drug designation for apatinib to treat gastric cancer in the European Union. The company simultaneously initiated site-initiation visits for a global phase 3 clinical trial targeting third-line gastric cancer, with plans to enroll patients across 12 countries.